Highlights
About
Monitoring Malignancies trough a Simple Blood Test
ST Innovative Diagnostics developed a novel blood-based malignancy monitoring test, based on research from Rabin Medical Center and Tel Aviv University. The company's proprietary technology & kit, measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across multiple malignancies.
POC Clinical studies have shown high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma. The technology shows promise for early detection of treatment resistance in NHL patients, facilitating timely transition to second-line therapies and preventing T-cell exhaustion and is planned to expand to solid tumor monitoring & diagnosis, including Metastatic Colorectal and Pancreatic Cancers.
Identity
| Name | ST Innovative Diagnostics |
|---|---|
| Slug | st-innovative-diagnostics |
| Type / kind | startup |
| Source _id | q65QgCbjfOdkqJni3e5t71sCt24FhThnlnKi0XTV9Mu0ggnmzHlYBb |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Be'er Ya'akov |
| HQ address | Simtat HaAnkor 12, Be'er Ya'akov, Israel |
Web & social
| Website | https://www.st-diagnostic.com |
|---|---|
| https://www.linkedin.com/company/103237856 |
Classifications
Funding
| Total raised | $70K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}